Rifampicin Resistance Treatment
For adolescents aged 14 and older and adults with rifampin-resistant tuberculosis, use the 6-month BPaLM regimen (bedaquiline, pretomanid, linezolid, and moxifloxacin) rather than longer 15+ month regimens. 1
Treatment Algorithm Based on Fluoroquinolone Susceptibility
If Fluoroquinolone-Susceptible:
- BPaLM regimen for 6 months (strong recommendation) 1
- Bedaquiline: 400 mg daily × 2 weeks, then 200 mg three times weekly × 24 weeks
- Pretomanid: 200 mg daily × 26 weeks
- Linezolid: 600 mg daily × 26 weeks
- Moxifloxacin: 400 mg daily × 26 weeks
- Administer with food 7 days/week, avoiding milk and antacids
- Directly observed therapy 5 of 7 days per week
If Fluoroquinolone-Resistant or Intolerant:
- BPaL regimen for 6 months (without moxifloxacin) 1
- Only if no previous exposure to bedaquiline and linezolid, or exposure <1 month
- Same bedaquiline, pretomanid, and linezolid dosing as above
Key Evidence Supporting This Approach
The 2025 ATS/CDC/ERS/IDSA guideline represents the most authoritative and recent recommendation, marking a paradigm shift from 15+ month regimens to 6-month all-oral therapy. This is based on the TB-PRACTECAL trial 2, which demonstrated that the 24-week BPaLM regimen had only 11% unfavorable outcomes versus 48% with standard care (37 percentage point difference), with significantly fewer grade 3+ adverse events (19% vs 59%).
Important Caveats and Limitations
Populations NOT eligible for 6-month regimens:
- Children under 14 years (though BDLLfxC regimen may be an emerging option) 3
- Complicated extrapulmonary TB: central nervous system, osteoarticular, or disseminated disease 3
- Patients with previous bedaquiline/linezolid exposure >1 month
For these excluded populations: Use individualized longer regimens (18+ months) based on drug susceptibility testing 4
Safety Monitoring Priorities
The most common serious adverse event is QTc prolongation (29.5% with oral regimens) 5. Monitor:
- Baseline and serial ECGs
- Electrolytes (potassium, magnesium)
- Hepatobiliary function (7.5% hepatotoxicity risk) 5
- Complete blood counts for linezolid-associated myelosuppression
Add pyridoxine (vitamin B6) 25-50 mg daily to prevent peripheral neuropathy 1
Clinical Outcomes
Culture conversion occurs rapidly (median 39 days) 6, with favorable end-of-treatment outcomes in 85% of patients 6. Quality of life and dyspnea scores improve significantly with treatment success 6.
The certainty of evidence is rated as "very low" by the guideline panel 1, but the strong recommendation reflects the substantial benefit over harm ratio—dramatically shorter treatment duration with better tolerability translates to improved adherence and reduced morbidity from both the disease and treatment toxicity.